328 related articles for article (PubMed ID: 32076595)
1. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
Oliva S; D'Agostino M; Boccadoro M; Larocca A
Front Oncol; 2020; 10():1. PubMed ID: 32076595
[TBL] [Abstract][Full Text] [Related]
2. Advances in minimal residual disease monitoring in multiple myeloma.
Wijnands C; Noori S; Donk NWCJV; VanDuijn MM; Jacobs JFM
Crit Rev Clin Lab Sci; 2023 Nov; 60(7):518-534. PubMed ID: 37232394
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
Front Oncol; 2022; 12():932852. PubMed ID: 36052251
[TBL] [Abstract][Full Text] [Related]
4. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
Mina R; Oliva S; Boccadoro M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32645952
[TBL] [Abstract][Full Text] [Related]
8. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
9. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
10. Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.
Urushihara R; Takezako N; Yoroidaka T; Yamashita T; Murata R; Satou K; Nakao S; Takamatsu H
EJHaem; 2023 Feb; 4(1):184-191. PubMed ID: 36819171
[TBL] [Abstract][Full Text] [Related]
11. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
12. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
13. Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients.
Zamagni E; Tacchetti P; Barbato S; Cavo M
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33142671
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
15. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
17. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S; Hillengass J; McCarthy PL; Holstein SA
Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S; Korde N; Lesokhin AM; Lendvai N; Hassoun H; Stetler-Stevenson M; Landgren O
Nat Rev Clin Oncol; 2015 May; 12(5):286-95. PubMed ID: 25622976
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
[No Abstract] [Full Text] [Related]
20. Minimal residual disease negativity by next-generation flow in non-CR myeloma patients.
Kim SM; Yang NE; Jeong D; Yun J; Ryu S; Yoon SS; Ahn YO; Lee DS
EJHaem; 2020 Nov; 1(2):563-566. PubMed ID: 35844993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
